Bronchogen
Also known as: Peptídeo brônquico
Molecular Identifiers
Overview
Bronchial bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in bronchial tissue and supports respiratory mucosa function. Used in short cycles for protection and regeneration of the respiratory system.
AEDL Ala-Glu-Asp-Leu Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in bronchial tissue
- Support for respiratory mucosa integrity
- Normalization of airway secretory function
- Modulation of bronchial inflammatory response
- Bioregulatory effect on bronchopulmonary epithelium
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-10 mg per day via subcutaneous injection |
| Frequency | Once daily |
| Timing | Morning or as per protocol |
| Duration | 10-20 days, cycled 2-4 times per year |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Freely soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Very stable short peptide — tolerates brief temperature excursions. |
Presentations & Preparation
Vials of Bronchogen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Bronchogen.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily
Dalargin
1-2 mg per injection (subcutaneous or intramuscular) · 1-2 times daily